Recent News

• 03.25.2026 - ICON, Advarra partnership aims to optimize trials, expand access
• 03.25.2026 - ICON partners with Advarra to launch connected site network model
• 03.25.2026 - ICON, Advarra partner on connected site network model
• 03.24.2026 - ICON and Advarra Introduce New ‘Research-Ready,’ Connected Site Network Model
• 03.16.2026 - Beyond viral suppression: Next-generation HIV therapeutics target reservoirs, broadly neutralising antibodies, and gene editing
• 03.02.2026 - Mission (im)possible? Efficient Global Antibody Drug Conjugate Product Approvals

Recent Filings

• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities